Andreas Jeromin,1 Jeffrey Randall,1 David H. Wilson,1 Kaj Blennow2, Henrik Zetterberg2,3
1Quanterix Corporation, Lexington, MA;2Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, SE-43180 Mölndal, Sweden 3UCL Institute of Neurology, London WC1N1PJ, UK
Background: There is increasing interest for the assessment of neurodegenerative biomarkers in blood, which have previously been restricted to cerebrospinal fluid (CSF). For example, methods for measuring total tau in serum and plasma have, until recently, been unavailable. We employed a new technology (Single molecule arrays, Simoa) capable of ultrasensitive protein measurements to measure changes of Abeta1-42 and total tau in different clinical applications, sports-related concussion and Alzheimer’s disease.